Skip to main content
Latest news
Browse specialties
Breast cancer Genitourinary cancers Lung & thoracic cancers
In focus
Next-generation sequencing: Emerging biomarkers in thyroid and NSCLCs ctDNA and bladder cancer: Current understanding and beyond ROS1 fusion-positive NSCLC NSCLC driver mutations: Discussing the importance of RET, ALK and ROS1 alterations in NSCLC Early-stage NSCLC management: Surgery, targeted treatment and immunotherapy ALK fusion-positive NSCLC: International approaches to management RET fusion-positive NSCLC: Informing on the use of pralsetinib for patients with RET fusion-positive, advanced NSCLC COVID-19 & cancer
Conferences
SABCS 2022 ESMO 2022 2022 ASCO Annual Meeting
About us
Medicine Matters Oncology
EXTENDED SEARCH
Top

01-01-2015 | Uterine cancer | Book chapter | Article

40. Hormone Therapy in Normal Postmenopausal Women and After Treatment for Endometrial Cancer

Authors: Nilanchali Singh, MD, DNB, Shalini Rajaram, MD, FAMS, Neerja Goel, MD, FAMS, FIMSA, FICOG, FFGSI

Publisher: Springer India

Login to get access

Abstract

About 20–25 % of women with endometrial carcinomas are diagnosed premenopausaly [1]. Hysterectomy and bilateral salpingo-oophorectomy the obligatory operative therapy, results in surgically induced menopause. The abrupt loss of estrogen gives rise to deficiency symptoms, mainly hot flushes, sleep disorders, and depressive mood, reducing quality of life. Hormone therapy (HT) has been used for decades to improve quality of life of menopausal women by reducing menopausal symptoms. The role of hormone therapy in women with endometrial cancer and risk of endometrial cancer in women on hormones will be discussed in this chapter.
Literature
1.
Mueck AO, Seeger H. Hormone therapy after endometrial cancer. Endocr Relat Cancer. 2004;11:305–14.CrossRefPubMed
2.
Crosignani PG. Effects of hormone replacement therapy. Int J Fertil. 1992;37 Suppl 2:98–103.PubMed
3.
Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women’s Health Initiative randomized controlled trial. JAMA. 2002;288(3):321–33.CrossRefPubMed
4.
Beral V. Breast cancer and hormone- therapy in the Million Women Study. Lancet. 2003;362(9382):419–27.CrossRefPubMed
5.
Langer RD, Manson JE, Allison MA. Have we come full circle – or moved forward? The Women’s Health Initiative 10 years on. Climacteric. 2012;15(3):206–12.CrossRefPubMed
6.
Oehler MK, Brand A, Wain GV. Molecular genetics and endometrial cancer. J Br Menopause Soc. 2003;9:27–31.CrossRefPubMed
7.
Romer T, Mueck AO. Endometrium und hormone substitution. Stuttgart: Georg Thieme Verlag; 1998.
8.
Seeger H, Wallwiener D, Mueck AO. Comparison of the effect of progesterone, medroxyprogesterone acetate and norethisterone on the proliferation of human breast cancer cells. J Br Menopause Soc. 2003;9:36–9.CrossRefPubMed
9.
Jane FM, Davis SR. A practitioner’s toolkit for managing the menopause. Climacteric. 2014;17:1–16.CrossRef
10.
Sturdee DW. Are progestins really necessary as part of a combined HRT regimen? Climacteric. 2013;16 Suppl 1:79–84.CrossRefPubMed
11.
Clavel-Chapelon F, van Liere MJ, Giubout C, Niravong MY, Goulard H, Le Corre C, et al. E3N, a French cohort study on cancer risk factors. E3N group. Eur J Cancer Prev. 1997;6(5):473–8.CrossRefPubMed
12.
Panay N, Hamoda H, Arya R, Savvas M. British Menopause Society & Women’s Health Concern recommendations on hormone therapy. Menopause Int. 2013;19(2):59–68.PubMed
13.
Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: heart and estrogen/progestin study follow-up (HERS II). JAMA. 2002;288:58–66.CrossRefPubMed
14.
Brinton LA, Felix AS. Menopausal hormone therapy and risk of endometrial cancer. J Steroid Biochem Mol Biol. 2014;142:83–9.PubMedCentralCrossRefPubMed
15.
Feeley K, Wells M. Hormone therapy and the endometrium. J Clin Pathol. 2001;54(6):435–40.PubMedCentralCrossRefPubMed
16.
Pike MC, Peters RK, Cozen W, et al. Estrogen-progestin therapy and endometrial cancer. J Natl Cancer Inst. 1997;89:1110–6.CrossRefPubMed
17.
Lacey JV, Leitzmann MF, Chang SC, et al. Endometrial cancer and menopausal hormone therapy in the National Institutes of Health-AARP Diet and Health study cohort. Cancer. 2007;109:1303–11.CrossRefPubMed
18.
Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen with and without progestins. J Natl Cancer Inst. 1999;91:1131–7.CrossRefPubMed
19.
Jaakkola S, Lyytinen HK, Dyba T, Ylikorkala O, Pukkala E. Endometrial cancer associated with various forms of postmenopausal hormone therapy: a case control study. Int J Cancer. 2011;128(7):1644–51.CrossRefPubMed
20.
Razavi P, Pike MC, Horn-Ross PL, Templeman C, Bernstein L, Ursin G. Long-term postmenopausal hormone therapy and endometrial cancer. Cancer Epidemiol Biomarkers Prev. 2010;19:475–83.PubMedCentralCrossRefPubMed
21.
Lacey JV, Brinton LA, Lubin JH, Sherman ME, Schatzkin A, Schairer C. Endometrial carcinoma risks among menopausal estrogen plus progestin and unopposed estrogen users in a cohort of postmenopausal women. Cancer Epidemiol Biomarkers Prev. 2005;14:172–31.CrossRef
22.
Grady D, Gebretsadik T, Kerlikowski K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol. 1995;85:304–15.CrossRefPubMed
23.
Hill DA, Weiss NS, Beresford SAA, Voigt LF, Daling JR, Stanford JL, Self S. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol. 2000;183:1456–61.CrossRefPubMed
24.
Persson I, Weiderpass E, Bergkvist L, Bergström R, Schairer C. Risks of breast and endometrial cancer after estrogen and estrogen-progestin replacement. Cancer Causes Control. 1999;10:253–60.CrossRefPubMed
25.
Lee SJ, Yeo SG, Kang SB, Park DC. Attitudes and practices of Korean gynecologists forwards hormone replacement therapy inendometrial cancer survivors. Eur J Gynaecol Oncol. 2013;34(6):513–7.PubMed
26.
National Comprehensive Cancer Network (NCCN). NCCN Clinical practice guidelines in oncology. Uterine neoplasms V.1.2010. Fort Washington: NCCN; 2010.
27.
de Villiers TJ, Gass MLS, Haines CJ, Hall JE, Lobo RA, Pierroz DD, Rees M. Global consensus statement on menopausal hormone therapy. Climacteric. 2013;16:203–4.CrossRefPubMed
28.
The North American Menopause Society. The hormone therapy position statement of the North American menopause society. Menopause. 2012;19(3):257–71.
29.
American College of Obstetricians and Gynecologists (ACOG). Hormone replacement therapy in women treated for endometrial cancer. Committee opinion 235. Int J Gynecol Obstet. 2001;73:283–4.CrossRef
30.
Creasman WT. HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat. 1999;4:217–25.PubMed
31.
Lee RB, Burke TW, Park RC. Estrogen replacement therapy following treatment for stage I endometrial carcinoma. Gynecol Oncol. 1990;36:189–91.CrossRefPubMed
32.
Chapman JA, DiSaia PJ, Osann K, Roth PD, Gillotte DL, Berman ML. Estrogen replacement in surgical stage I and II endometrial cancer survivors. Am J Obstet Gynecol. 1996;175:1195–200.CrossRefPubMed
33.
Suriano KA, McHale M, McLaren CE, Li KF, Re A, DiSaja PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. Obstet Gynecol. 2001;97:955–60.CrossRef
34.
Quella SK, Loprinzi CL, Sloan JA, Vaught NL, DeKrey WL, Fischer T, Finck G, Pierson N, Pisansky T. Long term use of megestrol acetate by cancer survivors for the treatment of hot flashes. Cancer. 1998;82:1784–8.CrossRefPubMed
35.
Farish E, Barnes JF, O’Donoghue F, Fletcher CD, Ekevall K, Hart DM. The role of megestrol acetate as an alternative to conventional hormone replacement therapy. Climacteric. 2000;3:125–34.CrossRefPubMed
36.
Mirkin S, Archer DF, Taylor HS, Pickar JH, Komm BS. Differential effects of menopausal therapies on the endometrium. Menopause. 2014;21(8):899–908. [Epub ahead of print].CrossRefPubMed
37.
Archer DF, Hendrix S, Gallagher JC, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab. 2007;92(3):911–8.CrossRefPubMed
38.
Labrie F, Archer D, Bouchard C, et al. Intravaginal dehydroepiandrosterone (Prasterone), the physiological and a highly efficient treatment of vaginal atrophy. Menopause. 2009;16(5):907–12.CrossRefPubMed
39.
Kulak Jr J, Ferriani RA, Komm BS, Taylor HS. Tissue selective estrogen complexes (TSECs) differentially modulate markers of proliferation and differentiation in endometrial cells. Reprod Sci. 2013;20(2):129–37.PubMedCentralCrossRefPubMed
40.
Mueck AO, Seeger H, Haasis R, Gohlke-Ba¨rwolf C, Schieber M, Schuchert A, Meinertz T. Effect of oral vs. transdermal estradiol on cGMP during exercise in women with coronary artery disease—randomized, double-blind, placebo-controlled cross over study. Circulation. 1999;100(18):1386.insert last page.
41.
Guttuso T, Kurlan R, McDermott MP, Kieburtz K. Gabapentin’s effects on hot flashes in postmenopausal women: a randomised controlled trial. Obstet Gynecol. 2003;101:337–45.CrossRefPubMed
42.
Johnson EB, Muto MG, Yanushpolsky EH, Mutter GL. Phytoestrogen supplementation and endometrial cancer. Obstet Gynecol. 2001;98:947–50.CrossRefPubMed
43.
Quaas AM, Kono N, Mack WJ, Hodis HN, Felix JC, Paulson RJ, Shoupe D. Effect of isoflavone soy protein supplementation n endometrial thickness, hyperplasia, andendometrial cancer risk in postmenopausal women: a randomized controlled trial. Menopause. 2013;20(8):840–4.PubMedCentralCrossRefPubMed
44.
Graziottin A. Loss of libido in the postmenopause. Menopausal Med. 2000;8(1):9–12.
45.
Chughtai B, Levin R, De E. Choice of antimuscarinic agents for overactive bladder in the older patient: focus on darifenacin. Clin Interv Aging. 2008;3(3):503–9.PubMedCentralPubMed
46.
Van Der Laak JA, De Bie LM, De Leeuw H, De Wilde PC, Hanselaar AG. The effect of Replens on vaginal cytology in the treatment of postmenopausal atrophy: cytomorphology versus computerised cytometry. J Clin Pathol. 2002;55:446–51.PubMedCentralCrossRefPubMed